Home

BioCardia has announced the publication of data from the initial open-label roll-in cohort that served as the precursor for the ongoing CardiAMP Heart Failure (HF) phase III clinical trial. Published in the International Journal of Cardiology, the study data shows that CardiAMP is a well-tolerated treatment in heart failure patients and demonstrated improved distance in six-minute exercise testing at six months and a trend toward improvement at one year. This 10-patient cohort was the feasibility test for the currently enrolling CardiAMP HF Phase 3 clinical trial.

The study, entitled “Point of care, bone marrow mononuclear cell therapy in ischemic heart failure patients personalized for cell potency: 12-month feasibility results from CardiAMP heart failure roll-in cohort,” followed 10 patients with chronic post-heart attack heart failure (NYHA class II and III) who underwent a 5ml bone marrow aspiration to determine cell potency using the patented CardiAMP cell potency assay followed by CardiAMP cell therapy, consisting of bone marrow mononuclear cell (BM MNC) enrichment and transendocardial injection of 200 million BM MNCs, at a subsequent single point-of-care visit. The study followed those subjects for 12 months and showed no serious adverse events related to bone marrow or cell delivery. Importantly, improvement at six months was observed in Six Minute Walk distance (+47.8 meters, p=0.01) and trended to improvement at 12 months (+46.4 meters, p=0.06). Echocardiographic data substantiated the improved performance of patients, as better contractility was seen of the heart.

“These results surpassed what we saw in our Phase 2 trial in similar NYHA Class I, II, and III ischemic heart failure patients. Utilizing our cell potency assay is an important component of the CardiAMP treatment process, as it is the potency of the patients’ own cells that facilitates the regeneration and, therefore, the therapy. The results for these 10 patients are a meaningful marker for the heart failure community as a whole, and we believe it bodes well for our larger trial, for which these first patients laid the groundwork,” said BioCardia chief medical officer Eric Duckers. “Our current CardiAMP HF trial is currently enrolling, and we anticipate full enrolment as early as the fourth quarter of 2021. In the meantime, we expect to receive the results from our data and safety monitoring board (DSMB) review by December 15, 2020.”

The published paper also reported 12-month trends toward improvement in a variety of cardiac functions, including left ventricular ejection fraction and recruitment of previously akinetic left ventricular wall segments. The 10-patient cohort also displayed trends toward improvement of NYHA heart failure functional class and overall quality of life.

Source CardiovascularNews

Duc Tin Clinic

Chia sẽ qua facebook bài: BioCardia shares early data from phase III CardiAMP cell therapy trial

Chia sẽ qua google bài: BioCardia shares early data from phase III CardiAMP cell therapy trial

Chia sẽ qua twitter bài: BioCardia shares early data from phase III CardiAMP cell therapy trial

Chia sẽ qua MySpace bài: BioCardia shares early data from phase III CardiAMP cell therapy trial

Chia sẽ qua LinkedIn bài: BioCardia shares early data from phase III CardiAMP cell therapy trial

Chia sẽ qua stumbleupon bài: BioCardia shares early data from phase III CardiAMP cell therapy trial

Chia sẽ qua icio bài: BioCardia shares early data from phase III CardiAMP cell therapy trial

Chia sẽ qua digg bài: BioCardia shares early data from phase III CardiAMP cell therapy trial

Chia sẽ qua yahoo bài: BioCardia shares early data from phase III CardiAMP cell therapy trial

Tin tức liên quan

Enrolment reaches midway point in trial of Early Bird bleed monitoring system

Eight-fold increased risk of heart attack seen in patients with subclinical obstructive coronary atherosclerosis

ACC 2023: REVIVED-BCIS-2 results challenge “long-held beliefs” on myocardial viability testing prior to PCI

Blood pressure successfully cut in RADIANCE II ultrasound renal denervation trial

New data examine mortality rates and cardiac damage in early-stage aortic stenosis patients

SUPPORT CONSULTANT

Make an Appointment

I am Nguyen Thanh Sang, born in 1990. Since the examination and treatment at the clinic Duc Tin, I am very grateful to the Doctor for explaining and sharing about my illness. During the treatment time in the clinic I was very caring staff of the clinic. Now my illness has improved in a good way. Expect more and more clinic to be able to save many patients.

I sincerely thank you !. Tel: 0938303275

Huynh Thi Muoi, born in 1940, was examined and treated at Duc Tin Clinic. I am very pleased about how to serve and care patients of the clinic. The doctor is committed to explaining and sharing with the patient.

Huynh Thi Muoi sincerely thank you! Phone number: 0972868746

As I said Duc Tin surgical clinin is where my family trust, hope to visit. Physicians caring, thoughtful, gentle to the patient. Nurses and staff clinic polite, cheerful and thoughtful. This clinic clean, sterile, so I would love to. Tel: +84949914060.

The doctor is very caring, attentive and very gentle nurse, courteous, affable with me. The clinic is clean, comfortable, polite. I enjoyed this faith. Every visit I was very relieved disease. Tel: 0839820792.

I was patient, had to clinics of Dr. Le Duc Tin. I see very conscientious doctor patient care, answer any questions and very dedicated staff from the receptionist to the children tested, nursing. Clinics very clean and spacious. I'm very satisfied. Tel: +841227880829.